USP7 and nonpapillary renal cell carcinoma: To improve the anti-tumor activity and durability of USP7 inhibitors, we performed a drug combination screen in OS-RC-2 cells from a collection of 16 drugs currently approved or in clinic trials for ccRCC patients and revealed that pharmacological inhibition of USP7 by P5091 significantly increased the sensitivity to afatinib and flavopiridol (Fig. 6a, b and Supplementary Fig. S4).